Hormonal Regulation of Systolic Blood Pressure in Response to the GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist, Liraglutide.

Trial Profile

Hormonal Regulation of Systolic Blood Pressure in Response to the GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist, Liraglutide.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms BOLT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Mar 2015 The primary endpoints have been amended, according to ClinicalTrials.gov record.
    • 24 Mar 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top